On August 26, 2026, Takeda Pharmaceuticals USA, Inc. and Takeda Pharmaceuticals International AG (collectively, “Takeda”) filed a BPCIA complaint in the U.S. District Court for the District of New Jersey against Polpharma Biologics S.A. (“Polpharma”), alleging that Polpharma’s vedolizumab biosimilar, PB016, will infringe six patents related to Takeda’s ENTYVIO (vedolizumab)….
On March 18, 2026, Sandoz announced a new license, development, and commercialization partnership agreement with Samsung Bioepis Co., Ltd. Under this agreement, the companies will collaborate on the development and commercialization of up to five biosimilar assets, with the potential for further collaboration. Sandoz will have exclusive global commercialization rights,…
Last week, Takeda announced that it has entered into a worldwide license and collaboration agreement (outside of Greater China) with Innovent Biologics for the development, manufacture, and commercialization of two late-stage oncology medicines, IBI363 and IBI343. According to Takeda, IBI363, a PD-1/IL-2α-bias bispecific antibody fusion protein, is being evaluated in…
Duality Biologics and GSK enter into an exclusive option agreement to exploit gastrointestinal cancer target, DB-1324 On December 4, 2024, Duality Biologics (“DualityBio”), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjugate (“ADC”) therapeutics, announced an exclusive option agreement with GSK for DualityBio’s ADC candidate,…